multiple sclerosis
Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data
April 20, 2016Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
Novartis and Microsoft team up for Kinect collab
March 8, 2016Manufacturing and Production, Research and Development Microsoft, Novartis, multiple sclerosis
Novartis has partnered with technology giant Microsoft; hoping to use its Kinect motion sensor to quantify whether its multiple sclerosis …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Biogen’s natalizumab fails Phase III endpoints
October 21, 2015Biogen, multiple sclerosis
Biogen’s natalizumab has failed to achieve clinical endpoints in a late-stage study to prove the drug’s potential in patients with …
Almirall presents new data on cannabinoid-based MS treatment
October 9, 2015Research and Development Almirall, multiple sclerosis
Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …
Positive late-stage results for Genentech’s ocrelizumab in different forms of MS
October 8, 2015Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab
Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
Novartis looks to new measure of Gilenya outcomes
October 8, 2015Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis
Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
Multiple Sclerosis treatment will be a $20bn market by 2024
October 7, 2015Research and Development multiple sclerosis
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …
Experts call for greater urgency in MS treatment
October 7, 2015Research and Development multiple sclerosis
A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …
Neurology comes to the fore
September 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology
Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
Novartis buys rights to GSK MS drug for up to $1 billion
August 21, 2015Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab
Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
Biogen to build billion-dollar plant in Switzerland
July 7, 2015Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis
Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …
Novartis MS drug scores positive late-stage trial result
April 21, 2015Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis
People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
